Clinical Report: Initial Retinal Volume Alterations Following Transition to Brolucizumab
Overview
This study evaluates early anatomical changes and intraocular inflammation following the switch to brolucizumab in patients with refractory neovascular age-related macular degeneration. Significant decreases in central foveal retinal thickness and pigment epithelial detachment volume were observed.
Background
Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness, and anti-VEGF agents are commonly used for treatment. However, some patients remain refractory to existing therapies, necessitating the exploration of alternative agents like brolucizumab. Understanding the anatomical changes following the switch to brolucizumab is crucial for managing potential intraocular inflammation.
Data Highlights
Parameter
Before IVBr
After IVBr
P-value
Central Foveal Retinal Thickness (CRT)
247 (130) μm
227 (94) μm
< 0.001
Pigment Epithelial Detachment Volume
0.18 (0.47) mm³
0.11 (0.19) mm³
0.04
Central Choroidal Thickness
159 (118) μm
168 (78) μm
0.018
Central Retinal Volume (CRV)
9.80 (1.40) mm³
9.70 (1.30) mm³
0.111
Key Findings
Switching to brolucizumab resulted in a significant decrease in central foveal retinal thickness (CRT).
Pigment epithelial detachment volume decreased significantly after the switch.
Central choroidal thickness increased post-treatment, indicating potential anatomical changes.
Three eyes exhibited intraocular inflammation (IOI) following brolucizumab injection.
In eyes without IOI, a significant decrease in central retinal volume (CRV) was observed.
Clinical Implications
The findings indicate the importance of monitoring for intraocular inflammation following treatment with brolucizumab.
Conclusion
The transition to brolucizumab in patients with refractory nAMD resulted in notable anatomical changes.
